Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.

Conditions

• Respiratory Tract Infections

Interventions

DRUG

PF-04287881

75 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 75 mg oral dose (prepared solution), given once

DRUG

PF-04287881

150 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 150 mg oral dose (prepared solution), given once

DRUG

PF-04287881

300 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 300 mg oral dose (prepared solution), given once

DRUG

PF-04287881

750 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 750 mg oral dose (prepared solution), given once

DRUG

PF-04287881

1000 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 1000 mg oral dose (prepared solution), given once

DRUG

PF-04287881

1250 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 1250 mg oral dose (prepared solution), given once

DRUG

PF-04287881

1500 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 1500 mg oral dose (prepared solution), given once

DRUG

PF-04287881

300 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 300 mg oral dose (prepared solution), given once

DRUG

PF-04287881

750 mg oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 750 mg oral dose (prepared solution), given once

DRUG

PF-04287881

1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once

DRUG

Placebo

placebo to match 1000 mg oral dose (prepared solution), given once

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-11-30

Primary Completion

2009-12-31

Completion

2009-12-31

Countries

• United States

Study Locations